Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guestimate:
1. Payment to Eurofins to complete job. I think PMCB had to make an earlier down payment.
2. They have mouths to feed: the ceo, cfo, cmo, crabtree and austrianova's sweet little 6 month deal.
The company needs to change strategy. focus on pc and license ciab for diabetes. I somehow remember Harvard has developed cells but needed a mouse trap like CIAB.
On sidelines watching.....
There is one event that would lead me to immediately buy Pharmactye stock
Have Waggoner and Crabtree each buy $250,000 of stock in Pharmactye. This would give me extreme confidence that this will suceed. So lets see if they do this???
I let almost a week elapse to listen again to the conference call. They missed on PC, Ascietes and Diabetes. Who knows what is happening to MJ?
As you mentioned in an earlier post, the company is trying to do too much.
They need to focus only on PC and license CIAB for diabeties.
CIAB is a very valuable asset. The company no longer has the time or money to spend to rework these studies.
Yes, unfortunately this is what is probably going on.
I do believe if the ceo submitted the ind this year the shareholders would have benefited. But the ceo did not get the job done. Why on earth did he use a second rate vendor to produce the MCB and WCB????
The ceo has not been forthcoming to the shareholders as evidenced at last weeks cc. I thought it was unusual to get stem cell license from austria nova while we had magellen cells. We know why now. The magellen cells do not work. With TD2 gone it is a whole new ballgame.
I would ony invest at .01 or
.02 as a wild card lottery.
Thanks for your observations.
Your are 100% correct. That is why I sold out.
The stock is worth a risk at .01-.02 which I believe we will get to before they submit an IND.
After 3 and half years I am out.....
Why in the world would you go to a third rate Italian facility to grow your cells..why not go to eurofins first???
What happend to TD2 and when did this happen? If they are out so am I.
I don't even know where we stand with diabetes?? Did we start the other islet cells recently???
Funny, I still think the technology is great but they are going to run out of money or fully dilute this stock
Heck, maybe china will be the answer to this??
But when you double your pay, redo the contract with AustriNova and pay them almost 1 million dollars over 6 months something does not add up.
I think the company could possibly turn itself around but waggoner and crabtree must resign first...
My condolences to my fellow longs.
The company has to get this IND submitted and soon. You cannot constantly delay and have an endless time frame. There can be no excuses.
The company's number one goal in 2016 was to get to trial by December 2016.
The company stated as the ASCO conference estimated start trial date December 2017.
Guess what? Hasn't happened and will not happen this year.
At some point you need to get the ball over the goal line and score a touchdown to win.
The CEO has not proven this. He can't even make his October 2017 time frame for updating shareholders. Yes he missed by a day but it is the principle behind it.
I have worked at several fortune 50 companies and if I missed a due date at work I would have been fired.
Yes, there is a date set.
Great find efood!!!!
Maybe Pharmacyte should have hired you instead of Morell !!!!LOL
Now if we can just get that darn IND submitted in my lifetime....
Unfortunately I agree with you.
Hopefully, we get a rough idea when the Ind will be filed. IMO best case scenario will be end of Dec or early Jan but more likely late jan or late feb. Otherwise there are real issues and time to bail.
Just keep expectations low......
Don't mean to be picky but I would have done the cc on October 31st just to meet the October time frame mentioned on the Facebook page. Once again, the CEO never meets a date. LOL!!!!
I would rather this be written as the CEO is not very good on cc calls.
He is going to briefly cover diabetes. How can you do that. I think it has been 2 years since we have any updates at all. God help us!!!!
Why has it taken over 9 months from meeting with the FDA and still no IND.
Inexcusable!!!!!!!
LAGUNA HILLS, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on Tuesday, January 17, 2017. The meeting is to discuss numerous aspects of PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).
8 business days left for company status update.
It is starting to look like it will not happen.
And no response to my email to the company several days ago asking about this update.
Again, very poor communication by the CEO and lapse of fiduciary responsibility to the company's shareholders....
Another day of no news. Nine business days left in October for the update.
I sent an email to the company yesterday asking if they were going to do an update on the company in October. I also included topics that they should cover. So far Pharmacyte has not responded to me.
Very bad communication......was yesterday's cannabinoid the update.. hope not.
This means no update today. 10 business days left in October....
The elephant in the room PMCB is ignoring...ah the IND....
No IND, No partnership, no funding from other sources....what is going on
with the company. HELP!!!!
9 months since FDA meeting and 8 months since last update....
So the countdown begins....11 business days left in October.
Hopefully, this CHINESE torture test (no pun intended LOL) will end soon...please
Merck is getting into the diabetes market:
Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake
http://www.investors.com/news/technology/small-cap-biotech-rockets-after-dows-merck-buys-10-stake/?src=A00220&yptr=yahoo
Will Lilly, Sanofi and NovoNordisk just sit there while either China or JNJ gets their hands on this technology?????
Now if we can just get that IND submitted......and get that company update....
It is time for the company to let us know where we stand. No more speculation from all please. And no more Facebook teases.
Let's reserve judgement on Pharmacyte until the company gives us an October update.
I have been here for 3 1/2 years so my patience is thin.
The CEO has done some good things and not good things.
One weakness is shareholder communication. He recently made a lot of decisions that needs more explanation ie the 50 million offering and changing the AustriaNova agreement. More details please. And too much facebook postings ie more canadians working at Pharmactye than Americans.
The recent hiring of two highly regarded scientists and a new well connected PR man eases my concerns greatly as they would not join what some people call a scam. I do not believe this is a scam but maybe poorly run. We need to get the show on the road and if not why the delays with specifics.
Rudy,
I think it will be a written PR rather than a cc. I would prefer this method as a cc call is not Pharmactye's strength.
Kudos to the company for listening to its shareholders and providing an update. Though I am cautious as to what we will learn....
Thanks oldmusky. Great job! Here are my questions:
1. Why can't Eurofins validate cells instead of AustriaNova? I would think it would speed up the process?
2. Will Pharmactye receive money back from Austria Nova since it is not producing the cells (Eurofins is producing)?
3. Will Pharmactye be charged more money by Eurofins if cells take longer to produce?
If yes, how much?
4. Is Pharmacyte still expecting to do a pivitol trial after IND submission or do we have to do a P1 assuming FDA approval?
Many thanks...
MetM
My PC clinical timetable since the CEO will not announce his:
1.Oct-Nov '17- Completion of MCB and WCB.
2.Dec '17-mid Jan '18 - Completion of testing the cell banks by AustriaNova.
3. Mid Jan-end Jan'18- Completion of IND by CRO and submission to the FDA.
4. End Feb '18/Early Mar '18 approval by FDA.
5. Early Apr '18 start of PC trial.
Now that wasn't too hard. Much more reasonable than starting the PC trial in December '17.
What's going on with Acites, Diabetes, MJ???????
The natives are restless and they should be.
There is zero chance the trial begins in December. At least the CEO is consistent-he never makes a date (estimate or not).
The CEO needs to communicate better. I thought this would be the case with the new PR person but I guess not.
Unfortunately, there will be more pain in the pps until the IND is submitted. I will buy more when the price declines more.
All said, I still believe in the end we will be very successful. When, who knows.....
Brian,
Here is the post:
esusun Thursday, 09/28/17 11:02:16 AM
Re: tulla236a post# 75513
Post #
75528
of 75630 Go
Kenn has recently said he thinks it is not possible ( at this point for PMCB to complete the MCB / WCB along with testing of cells ) for us to complete the steps reqd to actually file the IND in 2017 ...... He also said he expects the trial ( noting that FDA may requite a P1 before allowing us to run a pivotal trial ) will not happen until end of 2018
you all should know I am a Long , and a supporter of PMCB , but my patience is running thin . That does not mean I am selling my shs , I am not . none of them . Patience is going to be required .
There is no source or proof so I think this post is irresponsible. HOwever, IMO I do believe the IND will be issued late November or December of this year so patience will be required.This is fine with me.
Where did you receive this information(ie IND not filed in 2017)? Also, what is this P1 now all about??very confusing-and ouch....
If this is the case, then the CEO should come out with a public statement rather than string along investors.
Isn't placement in the body improved as well so it works better?
Is this new stock for JNJ??????
This is only speculation from my point of view:
1. We have funding in place for the PC trial from a large Pharma once the IND is accepted
2. If the pivotal trial is successful then I believe a large Pharma will buy out all of Pharmacyte including diabetes and MJ. This 6 month hardstop is all BS. They will know in several months as they can check imaging immediately after administering treatment.
3. If I am this large Pharma company I want 100% control of CIAB. Thus I want to buy out AustriaNova as well.
4. The $900,000 payment is incentive for AustriaNova to not sell (for a year) until the large Pharma feels comfortable that the treatment works in a larger population thus the pivotal trial. A small cost to pay if the treatment isnt successful. Avoid losing billions.
5. All companies play games for executive compensation. They take care of themselves first. Pharmacyte is no different. Just look at our CFO. A small time CPA that is overcompensated. But this is life.
6. If the company is sold for billions then I can live with all these side deals.
7. I do believe a large Pharma wanted protection that no other company would sweep in and buy CIAB.
Yes there is a 5 year agreement for Pharmacyte to buy austrianova but austrianova can sell itself in a year from now:
Additionally, for a period of one year from the date of the Term Sheet, Austrianova has agreed not to solicit, negotiate or entertain any inquiry regarding the potential acquisition of Cell-in-a-Box® and its Associated Technologies.
Interesting that we have stem cell rights but just for diabetes?? This is puzzling to me-what about magellan cells???
And why a 6 month contract with austrianova on payments????
I agree with brian that something big is happening...p
I think what the company is saying it needs to do pre-ind meeting with the FDA and do Phase I, Phase II and Phase III trials before it is a "product".
This makes sense.
However, this does not mean no news on diabetes. The company could announce positive preclinical results and or a partnership milestone agreement with a Pharm company. Remember the recent doctors that joined the company.They have an inside view on what is going on....so hang in there.
Thanks for your thoughts. Just wanted to add to your comments:
1.CIAB is a delivery system/platform.
2.CIAB contains biologic cells.
3.CIAB has gone thru Phase I and Phase 2 testing. So using the term theory is not correct. It has proven it works. The company needs to do a Pivotol trial to prove it works in a greater population. The same would be true for a big Pharma company.
Step 2 is why we are waiting for the company to submit its IND. It takes time to grow master and working cells.
Now 2 other points:
1. Each day we are closer to the IND submission.
2. Maybe the company will surprise us this month with a pr relating to diabetes and or ascites. They did not hire a new IR company for nothing.
Yeah, Just saw a news blip on tv." CRT a breakthrough therapy" then they said quickly at the end of the story that it has severe side affects. They did not go into detail on the side affects. LOL.
Great find Rudy!!!!
If I was a major Bio/Pharm I would buy Pharmactye now before it becomes very pricey. I have to believe that JNJ is not the only company interested in Pharmacyte.
Yes patience is important. But the IND needs to get done in 2017. Otherwise this stock collapses.
The frustration of longs come from the CEO issuing goals and not meeting them ie PC in clinical trial by December 2016......Right or wrong when you make a commitment you meet it period.
I am very comfortable where we are as a company right now. One item that would be of interest to me is what is going on with MJ and future plans...
perhaps a spinoff, deal with gwph or other companies????
Yes, the 6 month stop is all BS. The imaging company we contracted with can measure the effect IMMEDIATELY. I think it will be much much sooner than 6 months. Maybe 2-3 months maximum.
My question to the company is what are they doing to get a bidding war going and why would we have to wait for the filing for the IND to do this???? What about a preemtive strike by novo, sanofi, celg, pfe etc. Get the company cheaper now???
Right now the stock is like a US aircraft carrier dead in the water......just a sitting duck....
Just remember the recent hiring of two distinguished scientists should quell your doubts. They are here to win.
I think we are very close.
My question is if the JNJ rumor is true, what will Celgene and NovoNordisk do????? counter offer?????
Sorry but it is not for Pharmacyte.
Pharmacyte does not have an agreement with AustriaNova on stem cells. But as you indicated before we do own 14.5% of AustriaNova.
Excellent find!!!!
Pharmacyte's deal could be much bigger than Gerons' deal.....
The shareholders will win whether it is a partnership or a buyout.
My gut feeling now is we may have a surprise buyout.
GLTA
The two recent hires should convince investors that Pharmacyte is legit in both PC and Diabetes. Why else would they join???
Lets be patient. News should come in August or September. I think the news will be a game changer for shareholders.
All this talk is just noise. The company is not going to tell anyone what is going on in a piecemeal basis or before anything is finalized.
Very nice find!!! It is a small world.....